Home > GAMMAGARD Products > GAMMAGARD LIQUID SC > Consistency

GAMMAGARD LIQUID - SC Administration

Protecting life’s moments with consistent trough levels1,2

In the SC administration of GAMMAGARD LIQUID clinical study1

  • The median Ig trough level during intravenous treatment was 1010 mg/dL (95% CI: 940-1240)
  • The mean Ig trough level during intravenous treatment was 1050 ± 260 mg/dL2
  • The median Ig trough level during subcutaneous treatment was 1260 mg/dL (95% CI: 1060-1400)a
  • The mean Ig trough level during subcutaneous treatment was 1202 ± 282 mg/dLa

aTaken from pharmacokinetic analysis at the end of study period 4.


Study Design1,2

  • Multicenter, prospective, open-label, study (N=49 adults [n=31 16 years or older], adolescents [n=4 between 12 years and <16], and children [n=14 between 2 years and <12])
  • 4 study periods + optional extension

  • Mean weekly subcutaneous doses ranged from 182-191 mg/kg

Recommended dosing1

Important Considerations for Dosing1

  • Adjust dose according to IgG levels and clinical response as the frequency and dose of IgG treatment may vary from patient to patient
  • The patient’s clinical response should be the primary consideration in dose adjustment

References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxter Healthcare Corporation. April 2014. 2. Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31:323-331.

  • Your patients can get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Find Out How
  • Clinical Study Video Learn more about the clinical study of the subcutaneous administration of GAMMAGARD LIQUID.
    View study presentation

You are now leaving GAMMAGARD.com

Shire is not responsible for the privacy policy, the content or the accuracy of any web site accessed through a link on the GAMMAGARD.com site. A link to other web sites does not constitute an endorsement of Shire of the linked site, its products or services.

The browser window or tab for GAMMAGARD.com will remain open underneath the new browser window or tab. To return to GAMMAGARD.com at any time, close this tab or window.

Return to